Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07569029 · ClinicalTrials.gov registry record · Phase 1
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Not yet
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT07569029 is a Phase 1 study that has not yet begun recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 42 participants.
The verdict
NCT07569029, a Phase 1 study, has not yet begun recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health. The study will enroll about 42 participants at multiple study sites. Researchers will assess whether these vaccines can start or strengthen antibody responses against HIV. The study will also evaluate how a closely monitored planned pause in antiretroviral therapy affects these immune responses.
Interventions
- BIOLOGICAL DV700P-RNA 100 mcg
- BIOLOGICAL DV701B1.1-RNA 100 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07569029
The ClinicalTrials.gov registry entry for NCT07569029 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DV700P-RNA 100 mcg is the first listed.
NCT07569029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07569029 about?
NCT07569029 is a clinical study titled "A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies". This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health. The study will enroll about 42 participants at multiple study sites. Researchers will assess whether these vaccines can star...
What is the current status of trial NCT07569029?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-06-02. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07569029?
The interventions under investigation include: DV700P-RNA 100 mcg (BIOLOGICAL), DV701B1.1-RNA 100 mcg (BIOLOGICAL).
Who is sponsoring clinical trial NCT07569029?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.